Newsroom
Insights into LOVE
Welcome to our newsroom where we post news, events, and financial updates.
November 2, 2022
LOVE PHARMA INVESTEE, STARTON THERAPEUTICS, STRENGTHENS BOARD WITH NEW MEMBER (RE-RELEASE)
Please see the previously announced news from Starton Therapeutics Inc. VANCOUVER, BC, CANADA (November 2nd, 2022) – LOVE Pharma Co.
Read MoreOctober 20, 2022
NALTREXONE DEMONSTRATES PROMISING LONG COVID APPLICATION
Naltrexone primarily used to treat alcohol and or opioid has now shown promise in treating Long COVID at low doses1
Read MoreOctober 19, 2022
Love Pharma Closes Acquisition of Doc Hygiene
VANCOUVER, BC, CANADA (October 19th, 2022) – LOVE Pharma Co. (“LOVE” or the “Company”)(CSE: LUV) (FSE: G1Q0), is pleased to
Read MoreOctober 13, 2022
LOVE PHARMA – JOHNS HOPKINS UNIVERSITY PSILOCYBIN TRIAL ADVANCES TOWARD LAUNCH IN 2022
Dr. Albert Garcia Romeu will serve as head researcher for the Love Pharma’s MicroDoz sponsored trial to be conducted at
Read MoreOctober 11, 2022
LOVE PHARMA SIGNS LETTER OF INTENT TO ACQUIRE NALTREXONE THERAPEUTICS INC.
Love Pharma adding to its addiction treatment portfolio with transdermal IP acquisition for opioid antagonist drug Naltrexone Naltrexone primarily used
Read MoreSeptember 30, 2022
LOVE PHARMA SUBSIDIARY DOC HYGIENE DELIVERS SANITIZER PRODUCTS TO SUPPORT COMMUNITY NEEDS WITH OPERATION “CLEAN HANDS” and Closes Final Tranche of Financing
VANCOUVER, BC, CANADA (September 30th, 2022) – LOVE Pharma Inc. (“LOVE” or the “Company“) (CSE: LUV) (FSE: G1Q0) is pleased
Read MoreSeptember 21, 2022
LOVE PHARMA LAUNCHES PROPRIETARY E-COMMERCE PLATFORM FOR ONLINE SALES
LOVE’s online store launches with fully integrated e-commerce platform Consumers can now purchase the Company’s two proprietary branded products, BLOOM
Read MoreSeptember 7, 2022
Love Pharma Initiates First Steps Towards a Strategic Alliance with Starton Therapeutics with Investment in this Biotech Leader
Starton Therapeutics is a leading clinical stage Biotechnology Company based in New Jersey led by CEO and Chairman, Mr. Pedro
Read MoreAugust 25, 2022
LOVE PHARMA DELIVERS LETTER TO SHAREHOLDERS
Love Pharma President, Mr. Zach Stadnyk, delivers comprehensive report on the Company’s holdings and growth strategy Building upon the Company’s
Read MoreAugust 24, 2022
LOVE PHARMA INC. ANNOUNCES FIRST CLOSING OF FINANCING
VANCOUVER, BC, CANADA (August 24, 2022) – LOVE Pharma Inc. (“LOVE” and or “the Company”) (CSE:LUV) (FSE: G1Q0), announces it
Read More